For instance, targeting the CD33 myeloid marker in AML can produce an intolerable myelosuppression, making it necessary to proceed to allogeneic hematopoietic stem cell transplantation (alloHSCT) in all treated patients (53). The gene discussed is CD33; the disease is acute myeloid leukemia.